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Abstract
Background—Despite poor primary healthcare systems, free antiretroviral therapy (ART) has been
available in China for over 5 years. Virologic outcomes of Chinese patients receiving ART have not
been described at a national level.
Methods—A multi-stage cluster design was used in 8 provinces to randomly sample patients with
at least 6 months on first-line ART, stratified by 3 treatment duration groups. Viral load testing and
patient interviews were conducted and linked with national treatment database information. Data
collected were analyzed for association with viral suppression using multivariable modeling.
Adequate viral suppression was defined as viral load less than 400 copies/mL.
Results—Of 5,256 patients on ART, 3,894 patients met eligibility criteria from whom 1,153 were
analyzed. Overall, 72% demonstrated viral suppression; of these, 82%, 73%, and 67% of participants
on ART for 6–11 months, 12–23 months, and ≥24 months, respectively, showed viral suppression
(p<0.001). In a multivariable model, treatment received at locations other than county level hospitals
was less likely to achieve viral suppression, with greater odds for inadequate virologic response found
at village clinics (odds ratio [OR] 5.4; 95% confidence interval [CI], 2.9–10.1), township health
centers (OR, 3.1; CI, 1.7–5.6), and public health clinics (OR, 3.1; CI, 1.7–5.6). Patients receiving
didanosine-based regimens were more likely to experience an inadequate virologic response than
those receiving lamivudine-based regimens (OR, 3.9; CI, 2.7–5.7).
Conclusions—China’s national ART program is largely successful at suppressing viral load. Care
received outside of hospitals and regimens containing didanosine were associated with less favorable
virologic outcomes.
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China has approximately 700,000 people infected with HIV spread thinly among the population
of more than 1.3 billion [1]. China has confronted considerable challenges managing its HIV
epidemic. Previously the HIV epidemic in China was mostly among injection drug users and
poor farmers who donated plasma unsafely to illegal vendors [2–4], sexual transmission is now
on the rise [5]. In 2003, the Chinese Government implemented the National Free Antiretroviral
Treatment Program to emergently provide care to the rural population most heavily affected.
It was decentralized and relied upon local clinicians with limited training [6]. Having matured
over the last 5 years from an emergency response into a standardized treatment and care
program [3,6], more than 52,000 patients have received antiretroviral therapy (ART) [7].
To achieve universal access, the World Health Organization (WHO) recommends
decentralization and task shifting of HIV care to non-physician clinicians in resource-limited
settings [8–10]. The feasibility of implementing ART in developing countries has been
demonstrated, but previous studies of virologic outcome are limited to short treatment duration
periods, small numbers of treatment sites, and few treatment regimens. We report here virologic
outcomes of patients on first line therapy as well as factors associated with virologic failure in
a sample of adult patients receiving ART in 8 provinces in China.
Methods
Patients and ART Regimens
This study was approved by the institutional review board of the China Centers for Disease
Control and Prevention (China CDC). In accordance with Chinese [11] and WHO [12]
guidelines, initiation and monitoring of ART was based on clinical and immunologic
parameters. National guidelines provide for triple therapy with a first-line regimen of stavudine
(d4T) or zidovudine (AZT), lamivudine (3TC), and nevirapine (NVP) or efavirenz (EFV).
However, early in the treatment program, the supply of 3TC was limited leading to its frequent
substitution with didanosine (ddI). Viral load was not routinely tested and second-line therapy
was not yet widely available at the time of this study.
HIV care and treatment is provided at a variety of sites within the Chinese health care system
which is graded hierarchically based on the level of administrative division in which it is
located. County level hospitals and public health clinics are located within county capitals,
township health centers in smaller towns, and village clinics in rural settings. In village clinics,
township health centers, and public health clinics, care is provided by clinicians often lacking
a medical degree or extensive formal medical education [13]. HIV care providers usually
receive a structured two months of didactic and practical HIV care training.
National Database
The National Free ART Database, previously described [6,14], is an ongoing observational
database established in 2004 and maintained by the China CDC that contains baseline and
follow-up data from patients enrolled in the National Free Antiretroviral Treatment Program,
currently covering over 90% of patients on ART in China. For every visit to an HIV healthcare
provider, a form is completed and sent to the China CDC via DataFax (Clinical DataFax
Systems Inc., Hamilton, Ontario, Canada) for automated entry into the database [15].
Study Design and Sampling Method
A multi-stage cluster design was used to sample patients who received at least 6 months of
ART in China. Of 31 province level administrative units in mainland China, 8 provinces were
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purposively selected representing 88% of Chinese patients on ART. Of the provinces selected,
Henan, Shanxi, Anhui, Hubei, Shandong, and Jilin provinces have relatively large populations
of former plasma donors, patients who were infected by unsafe donation of plasma to illegal
vendors [4]. These provinces were among the first provinces to start the National Free
Antiretroviral Treatment Program [6]. Yunnan and Guangxi have high injection drug user and
sexually transmitted HIV patient populations and have experienced a rapid scale-up of
treatment [6,16].
For each province, the national treatment database was queried for counties with at least 50
patients receiving ART. Two of these counties were randomly selected, except for Shandong
and Jilin provinces in which 3 and 9 counties were sampled respectively due to the lower
number of patients on ART in each county. Patients who were on ART for less than 6 months,
aged less than 15, terminated treatment, had died, were lost-to-follow-up, or moved away from
their treatment center were excluded. Three treatment duration groups were established: 6–11,
12–23, and ≥24 months. For each county, stratified sampling was used according to the
minimum sample size derived from power calculation in order to select a fixed proportion of
subjects within each treatment duration group. If a particular county did not have enough
patients to fill each of the 3 treatment duration groups, all patients from that county were
included.
Data collection
Subjects were enrolled from April to June 2007. After informed consent was obtained, a study-
specific patient questionnaire was administered by trained research assistants eliciting
demographic, ART care condition, and adherence data. Blood samples were collected and
tested for CD4 cell count at county and provincial laboratories. Samples were also sent for
viral load testing at 8 provincial laboratories using either the COBAS Amplicor HIV-1 Monitor
(Roche Diagnostic Systems, Branchburg, N.J.) or NucliSens EasyQ HIV-1 (BioMerieux,
Marcy L’Etoile, France). Data from the National Free ART Database was also used for analysis.
Definitions
Immunologic failure was defined according to WHO guidelines (i.e., CD4 count <100 after 6
months on ART, below baseline, or <50% of peak) [12]. Adequate viral suppression was
defined as a viral load of less than 400 copies per mL. Viral load between 400 and 1,000 was
defined as indeterminate and 1,001 to 10,000 as probable virologic failure [17]. Definite
virologic failure was defined as greater than 10,000 copies per mL according to WHO
guidelines [12].
Statistical analysis
An intent-to-treat analysis of treatment regimen was used restricting analysis to initial treatment
regimen. Baseline characteristics were compared using the Kruskal-Wallis test for continuous
variables and the Pearson χ2 statistic for dichotomous and categorical variables. Hypothesis
testing was 2-sided with α = 0.05. Univariate comparisons were performed on 14 variables.
Variables with p<0.2 were retained for multivariable modeling using stepwise selection.
Clinical judgment was used to force potential confounders such as age, gender, and treatment
duration into final models. Multivariable logistics regression models were run with all patients
and stratified separately by treatment duration and by regimen. Results were reported as the
multivariate-adjusted odds ratio (AOR) with 95% confidence interval (CI) for the association
between predictor variables and failure to reach adequate viral suppression. Sensitivity
analyses were conducted with removal of indeterminate viral load results. Data were analyzed
using SAS version 9.1 (SAS Institute, Cary, NC).
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Patient Selection and Characteristics
The 24 selected counties had provided ART to 5,256 patients of whom 926 (18%) were
excluded because they received ART for less than 6 months, 23 (0.4%) because they were
below 15 years of age, and 3 (<0.1%) because they were not receiving ART for free. Of 4,304
patients remaining, 237 (6%) patients were known to have died, 52 (1%) terminated ART, 84
(2%) were lost-to-follow-up, and 37 (1%) moved away.
From the remaining 3,894 eligible patients, 1,170 (30%) were selected using stratified random
sampling as described above. Data from 1,153 patients were available for analysis. Baseline
demographic characteristics at the time of ART initiation are shown in Table 1. The median
age was 39 years (interquartile range [IQR] 34–46) and 56% of patients were male. Reported
transmission routes were 59% history of plasma donation, 8% injection drug use, 25% sexual
transmission, and 8% other.
Treatment Conditions and Outcomes
Median time on ART was 22.8 months (IQR 14.2–35.6) with a median duration of 9.1 months
in the 6–12 month group, 18.9 months in the 12–24 month group, and 35.9 months in the ≥24
month group. Initial regimens consisted of NVP or EFV, plus AZT or d4T, plus ddI or 3TC,
with 3% on other regimens. In total, 51% of patients were started on 3TC-based regimens and
46% on ddI-based regimens with 3TC use increasing in those initiating ART more recently.
In the ≥24 month group, ddI was used in 91%, 82%, 51%, and 15% of regimens at village
clinics, township health centers, public health clinics, and county-level or above hospitals,
respectively (p<0.001). In the 6–11 month strata, ddI use continued in village and township
health centers with 61% and 56% patients starting a ddI-based regimen but declined at public
health clinics and county-level hospitals to 4% and 1%, respectively.
Median baseline CD4 cell count was 119 (interquartile range [IQR] 40–199) cells per mm3
with data missing for 21% of participants. Treatment locations were divided between 23%
village clinics, 27% township health centers, 29% public health clinics, and 21% county level
hospitals. Self-reported 100% adherence in the previous week was 92%.
Viral suppression (HIV viral load < 400 copies/mL) stratified by duration on ART was 82%,
73%, and 67% for participants on ART for 6–11 months, 12–23 months, and ≥24 months,
respectively. Probable virologic failure (HIV viral load 1,001–10,000 copies/mL) was found
in 6%, 8%, and 12% of patients and definite virologic failure (HIV viral load > 10,000 copies/
mL) was found in 10%, 14%, and 18% of patients, among the same 3 treatment duration strata.
For 4% of patients, viral load was indeterminate (400–1,000 copies/mL). Virologic outcomes
by time on first line ART regimen and treatment facility are shown in Figure 1A for patients
receiving 3TC-based regimens, Figure 1B for patients receiving ddI-based regimens, and
Figure 1C for the whole study population. At the time of viral load testing, 18%, 13%, and
14% of subjects in the 6–11 month, 12–23 month, and ≥24 month groups, respectively,
demonstrated immunologic failure. Discordance between immunologic and virologic
responses is shown in Table 2. Combined, 66% of patients achieved both a virologic and
immunologic response, 6% virologic alone, 20% immunologic alone, and 9% no response.
Predictors of Viral Suppression
Five treatment characteristics were included in the age and gender adjusted multivariate
modeling: ART duration, ART regimen, site type, regimen switch, and missed pills in the last
7 days. Adjusted odds ratios for failure to reach viral suppression are shown in Table 3. Care
received at county level hospitals was superior to that received elsewhere with adjusted odds
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ratios for failure to reach viral suppression of 5.4 (95% CI, 2.9–10.1) for village clinics, 3.1
(1.7–5.6) for public health clinics, and 3.1 (CI, 1.7–5.6) for township health centers. Patients
receiving ddI-based regimens experienced inadequate virologic response more frequently than
those receiving 3TC-based regimens (AOR, 3.9; CI, 2.7–5.7). Missing pills in the last 7 days
was also associated with inadequate virologic response (AOR, 1.9; CI, 1.2–3.0). Patients in
longer treatment duration groups showed an insignificant trend towards higher failure.
When results were stratified into individual models for each treatment duration group,
compared to treatment at county level hospitals, treatment at all other facilities in the 12–23
month group and villages in the ≥ 24 month group was associated with failure to reach viral
suppression. Compared to 3TC-based regimens, ddI-based regimens showed significantly
increased AORs for failure to achieve viral suppression in all three treatment duration groups.
Less than 100% adherence was associated with failure to achieve viral suppression only for
the 6–11 month treatment group. Having changed regimens was associated with failure in the
≥24 month group.
Further stratification by drug regimen continued to demonstrate association of treatment
facility and virologic success. Compared to patients receiving care in county level hospitals,
adjusted odds ratios for failure to reach viral suppression, among patients receiving 3TC-based
regimens, were 5.3 (CI, 2.1–13.3) for village clinics, 3.4 (1.6–6.9) for public health clinics,
and 4.3 (CI, 2–9.4) for township health centers, and among those receiving ddI-based regimens,
were 8.3 (CI, 2.1–33.5) for village clinics, 4.4 (CI 1.1–18.0) for public health clinics, and 3.9
(CI, 0.97–15.5) for township health centers.
The above associations continued to show significant relationships upon additional
multivariate modeling adjusting for baseline CD4 count for the subset of patients with existing
data, with the exception of regimen switch in the ≥24 month model. Upon sensitivity analysis,
when indeterminate results were removed, all above findings maintained significant
relationships except for facility type and treatment outcome association in the ≥24 month model
and public health clinic inferiority in the ddI model.
Discussion
This is the first study in China to evaluate virologic suppression among a nationally selected
sample of adult HIV-infected patients on ART. The findings demonstrate virologic success for
the majority of adults receiving ART and show that initial regimen choice and type of care
delivery site significantly affected virologic outcomes in 8 provinces in China. Overall, 72%
of patients sampled demonstrated viral suppression with lower rates seen among those with
longer treatment duration. Patients who were started on regimens containing ddI instead of
3TC experienced less favorable outcomes. Treatment delivered at county hospitals showed
better virologic outcomes than that delivered elsewhere, with those patients treated at rural
village health care facilities having the highest rate of virologic failure.
Virologic outcomes in this study compared favorably to those reported elsewhere. In studies
of ART from developing countries worldwide, virologic control variably defined as viral load
less than 200–500 has ranged from 72 to 90% at 6 months [18–20], 50 to 86% at 12 months
[18,19,21–24], and for one study 81% at greater than 24 months [19]. An early clinical trial in
developed countries using an AZT+ddI+NVP regimen only reduced viral load to under 400 in
50% of patients after one year of therapy [25]. Combined analysis of triple combination therapy
trials shows non-nucleoside reverse transcriptase inhibitor regimens to reduce viral load to less
than 400 in 77% of patients at 24 weeks and 73% at 48 weeks [26].
In the current study, ddI-based regimens consistently demonstrated less favorable outcomes
than those containing 3TC. Few existing studies have directly compared ddI and 3TC
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containing regimens [27]. While one trial showed superiority of AZT+3TC over ddI+d4T
containing regimens [28], another showed no difference in virologic response between AZT
+3TC+EFV and ddI+3TC+EFV regimens [29]. The few patients (9%) in this study reporting
any missed pills in the last week demonstrated worse outcomes, consistent with prior work
showing increased virologic failure with adherence under 95% [30]. Baseline CD4 count failed
to predict virologic failure in a multivariable model of this population.
Our findings show that patients who received care in rural village clinics were significantly
more likely to fail to achieve viral suppression than those in county-level hospitals staffed by
trained physicians. Patients treated at public health clinics and township health centers also
had less favorable outcomes, but this relationship did not reach statistical significance in models
stratified by treatment duration. Although 3TC use was higher in county level hospitals
suggesting confounding of treatment facility and regimen, when patients were compared only
with others receiving the same treatment regimen, treatment facility remained significantly
associated with virological outcome.
Since its inception in 2003, China’s HIV treatment program has been decentralized to village
and township health centers in close proximity to the largely rural HIV-infected patient
population. Task shifting to provision of ART by non-physicians and decentralization to rural
clinics has been promoted by the WHO with excellent clinical outcomes in prior studies in the
developing world [9,24]. However, previous virologic outcome studies involving nonphysician
clinicians have been limited to small geographic regions that received extensive support and
training [31]. Task shifting is most successful when community health workers or nurses
receive regular supervision from experienced ART providers [24]. Scaling up such oversight
in China is challenging as there are over 3,700 sites of ART delivery spread across a large
country. Regimen choice in China has expanded such that ddI is now used in less than 10% of
initial ART regimens. Future efforts will focus on strengthening training programs for HIV
care providers to improve the quality of care in remote clinics.
Determining viral load in a representative sample of HIV-infected patients on first-line ART
is important for managing a maturing national treatment program. Excellent clinical and
immunologic outcomes observed over short periods cannot capture the subtleties of treatment
success and failure that virologic outcomes provide. Patients with discordant immunologic and
virologic outcomes, accounting for 26% in this study, have shown significantly higher
mortality in prior studies [32,33]. If monitoring for treatment failure by clinical and
immunologic criteria alone, some patients may be switched too early [34] and others too late
[35] leading to drug resistance [36,37].
The present study was limited by its cross-sectional nature. Only patients on therapy for greater
than 6 months were considered; early failure and mortality were not studied. The ten percent
of patients missing due to mortality, treatment termination, and loss to follow up likely
introduce selection bias. However, their numbers are likely insufficient to alter the conclusions
derived from multivariable modeling. If such missing patients are all considered failures, the
overall projected virologic suppression rate of patients on therapy longer than 6 months would
be 65%, thus confirming the overall high virologic suppression rate. Patients with
indeterminate viral loads of 400–1,000 copies per mL could not be retested in this study, but
were considered failures to maintain a conservative estimation of virologic suppression.
Although cross-sectional assessment of virologic suppression is inherently inferior to
longitudinal evaluation, where the availability of antiretroviral therapy predates that of viral
load testing, cross-sectional evaluation may provide valuable insight in such situations where
longitudinal study is impossible.
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The National Free Antiretroviral Treatment Program in China has demonstrated reduced HIV-
related mortality [4,7,14]. In this study, virologic outcomes, previously unreported on a
national level were shown to be equal or superior to those reported in developing and even
developed countries when similar methods were used. As the National Free Antiretroviral
Treatment Program continues to further expand, intensive efforts will be required to ensure an
increased drug supply and improved training and supervision, especially in rural segments of
the health care system. Owing in part to the results of this study, financial support is now
provided for free annual viral load testing nationwide.
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Virologic response divided by treatment duration and facility type for patients with initial
regimens containing lamivudine (A), for patients with initial regimens containing didanosine
(B), and for the whole study population (C) among a stratified random sample of patients in 8
provinces in China, 2007
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Table 2
Discordance of immunologic and virologic responses to ART by treatment duration group among a stratified




















6–11 151 (72) 21 (10) 22 (11) 16 (8)
12–23 289 (70) 14 (3) 73 (16) 40 (10)
≥24 323 (61) 28 (5) 131 (25) 44 (8)
Total 763 (66) 63 (6) 226 (20) 100 (9)
Note. Immunologic response was defined according to WHO guidelines as after 6 months of treatment a CD4 count of greater than 100, baseline, and
50% of peak. Virologic response was defined as a viral load of less than 400 copies per mL after 6 months.
VL, viral load suppression; CD4, CD4 count response
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